The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes

Immunology Letters

Volumn 60, Issue 1, 1998, Pages 57-60

  Dewit, Dominique ^a   Gourlet, Philippe ^a   Amraoui, Zoulikka ^a   Vertongen, Pascale ^a   Willems, Fabienne ^a   Robberecht, Patrick ^a   Goldman, Michel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

IL 12; LPS activated monocytes; RO25 1533; TNF

Indexed keywords

CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 12; RO 251553; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL;

HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MITOGENS; MONOCYTES; PEPTIDES, CYCLIC; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031892714     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(97)00129-6     Document Type: Article

References (15)

1. [1] S.I. Said, V. Mutt, Science 169 (1970) 1217-1218.
2. [2] M. De la Fuente, M. Delgado, M. DelRio, E. Garrido, J. Leceta, A. Hernanz, R.P. Gomariz, Peptides 15 (1994) 1157-1163.
3. [3] Z. Xin, H. Tang, D. Ganea, J. Neuroimmunol. 54 (1994) 59-68.
4. [4] A.M. Stanitz, D. Befus, J. Bienenstock, J. Immunol. 136 (1986) 152-156.
5. [5] M. Rola-Pleszczynski, D. Bolduc, S. St-Pierre, J. Immunol. 135 (1985) 2569-2573.
6. [6] M. De la Fuente, M. Delgado, M. DelRio, C. Martinez, R.P. Gomariz, Regul. Pept. 48 (1993) 345-353.
7. [7] M. O'Donnell, R.J. Garippa, N. Rinaldi, W.M. Selig, B. Simko, L. Renzetti, S.A. Tannu, M.A. Wasserman, A. Welton, D.R. Bolin, J. Pharmacol. Exp. Ther. 270 (1994) 1282-1289.
8. [8] M. O'Donnell, R.J. Garippa, N. Rinaldi, W.M. Selig, J.E. Tocker, S.A. Tannu, M.A. Wasserman, A. Welton, D.R. Bolin, J. Pharmacol. Exp. Ther. 270 (1994) 1289-1294.
9. [9] P. Gourlet, P. Vertongen, A. Vandermeers, M.C. Vandermeers-Piret, J. Rathé, P. De Neef, M. Waelbroek, P. Robberecht, Peptides 18 (1997) 403-408.
10. [10] A. Hernanz, E. Tato, M. De la Fuente, E. de Miguel, F. Arnalich, J. Neuroimmunol. 71 (1996) 25-30.
11. [11] N. Romani, S. Gruner, D. Brang, E. Kämpgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P.O. Fritish, R. Steinman, G. Schuler, J. Exp. Med. 180 (1994) 83-93.
12. [12] T.B. Usdin, T.I. Bonner, E. Mezey, Endocrinology 135 (1994) 2662-2680.
13. [13] A. Danek, M.S. O'Dorisio, T.M. O'Dorisio, J.M. George, J. Immunol. 131 (1983) 1173-1177.
14. [14] P. Vertongen, C. Devalck, E. Sariban, M.H. De Laet, H. Martell, F. Paraf, P. Hélardot, P. Robberecht, J. Cell. Physiol. 167 (1996) 36-46.
15. [15] M. Goldman, A. Marchant, L. Schandené, Ann. New York Acad. Sci. 796 (1996) 282-293.